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Abstract 
We investigated the effect of α-linolenic acid (ALA) in protecting the heart from injury caused by 
β-adrenergic overstimulation.  
ALA role was studied either on isoproterenol (ISO)-treated isolated rat cardiomyocytes (H9c2 cells) 
or in in vivo rat hearts. On isolated cardiomyocytes in vitro the involvement of kinases (Src and 
PI3K) in protection was tested using the specific inhibitors (PP2 or LY294002 respectively), while 
the role of caveolae was assessed by their disruption with methyl-β-cyclodextrin. 
The rats underwent either a normal chow diet or, alternatively, an ALA-enriched diet before, during 
and throughout 60 days after 5 days of isoproterenol administration. Before sacrifice, the 
hemodynamic changes were measured with echocardiography. In the explanted hearts, histological 
changes together with molecular markers of cardiac fibrosis and hypertrophy were evaluated. 
On H9c2 cell ALA abolished the ISO-induced reduction of viability. This effect was suppressed by 
both PP2 or LY294002 inhibitors and methyl-β-cyclodextrin caveolae disrupter. In the rats ALA 
prevented ISO-induced myocardial fibrosis and hypertrophy and kept cardiac mechanical function 
as in the control. It also counteracted the increased expressions of transforming growth factor-β 
(TGF-β) and β-myosin (β-MHC), the decreased expression of tissue inhibitor metalloproteinase-1 
(TIMP-1) and the enhanced activity of matrix metalloproteinase-2 (MMP-2). 
In conclusion, ALA-induced protection requires the integrity of caveolae where β2-adrenergic 
receptors (β2ARs) are restricted and mediate the activation of Src-PI3K protective pathway. By 
preserving this β2ARs pro-survival pathway, ALA-enriched diet protects the heart against ISO-
induced fibrosis and hypertrophy. 
 
Keywords: α-linolenic acid; caveolae; isoproterenol; myocardial fibrosis; myocardial hypertrophy; 
PI3K. 
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Introduction 
An increased sympathetic stimulation may occur in either cardiovascular or non-cardiovascular 
diseases 1. While the formers include hypertension, heart failure and ischaemic heart disease, the 
latters consist in diseases of the autonomic nervous system, metabolism and kidney 2-5. The 
prognosis of patients suffering from sympathetic hyperactivity is sometimes very poor, mainly if 
associated with ageing, heart failure and severe kidney disease 1. 
A feedback seems to exist between sympathetic overactivity and the severity of pre-existent 
cardiovascular diseases. In fact, a positive correlation has been demonstrated between infarct size 
and the subsequent increase in norepinephrine plasma level 6 as well as between elevated cardiac 
norepinephrine concentration and worsening of heart failure, occurrence of arrhythmias and sudden 
death 7. Actually, an increased β-adrenergic activity accelerates the progression of myocardial 
damage and is capable to produce necrosis even in non-ischemic hearts 8.  
The most common morphological changes induced by sympathetic overstimulation consist in 
myocardial fibrosis and hypertrophy 9-11. Indeed, fibrosis is generally characterized by excessive 
production, deposition and shrinking of extracellular matrix (ECM) caused by unbalance between 
synthesis and degradation 12 and it is usually associated with ventricular hypertrophy 13. Since this 
process is not remissible, the only possibility to avoid cardiac remodeling is to prevent the death of 
cardiomyocytes and the onset of fibrosis. 
A large body of evidence is in favour of a potential protective effect of seafood-derived omega-3-
polyunsaturated fatty acids (PUFAs), e.g. eicosapentaenoic acid (EPA) and docosahexanoic acid 
(DHA), against coronary heart disease and sudden cardiac death 14, 15. In contrast, only a few studies 
have been devoted to clarify the effects mediated by plant-derived PUFAs, such as α-linolenic acid 
(ALA), on various cardiomyopathies. These studies gave uncertain results 16-19 inasmuch as ALA 
supplementation has been reported to be associated only with a slight reduction of cardiovascular 
risk 19. Since PUFAs cannot be synthesized by humans, they should be better supplemented with an 
appropriated diet. Compared to EPA and DHA, ALA is more affordable and widely available. 
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Recently, it has been reported that ALA treatment restores caveolin-3 expression in neonatal 
cardiomyocytes 20 reverting the tumor necrosis factor-α receptor response from pro-apoptotic to 
anti-apoptotic. 
The present investigation was designed to ascertain whether ALA can avoid the myocardial injuries 
triggered by β-adrenergic overstimulation. Firstly, we assessed the triggering of pro-survival 
pathways in an in vitro model (H9c2 rat cardiomyocytes). Then, we studied the effects of an ALA-
enriched diet 18, 20, 21 in adult Wistar rats, which were repeatedly injected with isoproterenol (ISO). 
This treatment can mimic the effect of β-adrenergic overstimulation and cause infarct-like 
myocardial injuries 22, 23 through β1-adrenergic receptor (AR) binding 24.  
 
Materials and Methods 
Data mining 
ProteinQuest™ literature mining tool (BioDigitalValley S.r.l., Pont-Saint-Martin, Aosta, Italy) and 
Reactome FI app 25 for Cytoscape 26 version 3.2.0 (http://www.cytoscape.org) were used to detect 
and analyse correlations and interactions in the β-adrenergic receptor downstream signaling 
pathways (see Supplementary data). Among them, we selected for investigation the molecular 
targets involved in cell survival, fibrosis and hypertrophy onset (Fig. S1). 
 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (Saint Louis, MO, USA) except where 
otherwise indicated. 
 
In vitro Studies 
H9c2 cell treatments and viability assay 
The embryo rat cardiomyocyte cell line H9c2 was a generous gift from Dr. Claudia Penna 
(University of Turin). Cells were standardly cultured in 75 cm2 TPP® flasks (TPP Techno Plastic 
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Products AG, Trasadingen, Switzerland) in RPMI-1640 medium (PAA Laboratories GmbH, Cölbe, 
Germany) supplemented with 10% fetal calf serum (FCS) (PAA Laboratories GmbH), 100 U/ml 
penicillin G, 40 µg/ml gentamicin sulfate and 2.5 µg/ml amphotericin B at 37 °C in a humidified 
5% CO2 atmosphere. 
To assess the protective effect of ALA against a severe isoproterenol-induced cell damage, serial 
ISO concentrations ranging from 50 µM to 1 mM were tested. This procedure allowed us to identify 
the ISO concentration able to induce a reduction of cell viability by about 50% after 24 h of 
incubation (not shown). 
H9c2 cells were plated at the density of 3 × 104/well in 96-well plates (Becton Dickinson Labware, 
BD Italia, Buccinasco, Milano, Italy). The day after, cells were treated in accord with one of the 
following protocols: (i) twenty four hours of incubation in medium added with ISO (250 µM); (ii) 
twenty four hours of incubation in medium added with ALA (20 µM) 20, followed by other 24 hours 
of incubation in medium added with ISO and ALA at the same concentrations; (iii) one hour of 
pretreatment with the Src kinase inhibitor 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine alone (PP2, 10 µM); (iv) one hour of pretreatment of with the 
PI3K inhibitor LY294002 alone (100 nM); (v) one hour of pretreatment with the caveolae disrupter 
methyl-β-cyclodestrin (MβCD, 2.5 mM). For these last three conditions, pre-incubation was 
followed by the same protocol of (ii) group, but in the presence of the inhibitor; and, vi) untreated 
H9c2 cells were used as control.  
Cell viability was then assessed after the injury by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) 27. Briefly, MTT was added to the medium (final concentration 0.5 
mg/ml) and cells were further cultured for 3 h. Then, medium was replaced with an equal volume of 
dimethyl sulfoxide. The MTT absorbance was read at 560 nm with an Asys UVM-340 microplate 
reader (Biochrom, Cambridge Science Park, Cambridge, UK). MTT data were expressed as 
percentage of the control. Experiments were done in triplicate. 
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In vivo Studies 
Animals 
Two month-old male Wistar rats (Harlan-Italy, S. Pietro al Natisone, Italy) received humane care in 
compliance with Italian law (DL-116, January ST-segment 27, 1992) and in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996). The purposes and the protocols of the studies 
have been approved by the Ministero della Salute, Rome, Italy and by the Ethical Committee of the 
University of Turin, Turin, Italy. 
 
Experimental model 
Forty-two rats were randomly divided into three groups (n=14 each): Control group (CTRL), ISO 
group and ALA-ISO group (Fig. 1). The experimental period included 7 days of acclimatization, 5 
days of treatment and further 60 days of observation for a total of 72 days. In CTRL, the rats 
received a daily subcutaneous injection of 0.5 ml of saline solution during the treatment period, 
while in ISO group saline solution was replaced by 100 mg/kg of isoproterenol 23, 28. Both these 
groups were fed with a standard chow diet (Harlan Laboratories S.p.A., Udine, Italy) ad libitum for 
the entire experimental period. The animals of the ALA-ISO group were treated as those of the ISO 
group, but they were fed ad libitum with an ALA-enriched diet proposed and validated by 
Fiaccavento et al 18 from the first day of the acclimatization period to the sacrifice. The diet, 
consisting of carrots, apples and flaxseed (20:50:30 w/w), provides macro- and micronutrients 
needed for maintenance of animal health as well as the standard chow 18. On the basis of the content 
in ALA of flaxseed as reported by Rodriguez-Leyva et al.29, we estimate that each animal took 
2.85g/day of ALA. 
The weight of the animals was checked every 7 days. At the end of the experimental period, the rats 
were anaesthetized and the hearts were rapidly excised and weighed. Heart weights were 
normalized for the corresponding body weight of each animal to calculate heart/body weight ratio. 
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Then, the hearts were either fixed for histological examination or immediately snap frozen in liquid 
nitrogen and stored at -80°C until they were processed for biomolecular analysis. 
 
Heart function assessment 
Left ventricular ejection fraction (EF) and fractional shortening (FS) were assessed in all animals at 
the beginning of the acclimatization period as well as 30 and 60 days after the last subcutaneous 
injection. EF and FS were evaluated using an echocardiographic system equipped with a 7.5-MHz 
transducer (ESAOTE-MEGAS, Esaote, Genova, Italy). Briefly, the rats were anesthetized with 
ketamine (100 mg/kg) and xylazine (5 mg/kg). Then, the animals were tied in supine position on a 
pad and the chest was shaved to avoid the presence of air between the skin and the probe. At each 
time point, EF and FS were measured 5 times in each animal and the values were averaged. 
 
Histological examination 
Hearts were fixed with 4% paraformaldehyde, embedded in paraffin and then sliced to obtain 4 µm 
thick serial ventricular sections. Slices were stained with the Masson’s trichrome (Bio-Optica, 
Milan, Italy) in accordance with the manufacturer’s instructions and blindly examined. 
To evaluate the extension of fibrosis, photomicrographs of Masson’s trichrome stained ventricular 
sections were taken (100× magnification) using a Leica DM4000B microscope equipped with DFC-
320 Leica digital camera (Leica Microsystems, Wetzlar, Germany). Blue areas, which correspond to 
collagen deposition, were “color-range” selected with PhotoShop CS4 (Adobe Systems Inc., San 
Jose, CA, USA) and quantified with ImageJ Software (U.S. National Institutes of Health, Bethesda, 
MD, USA, http://rsb.info.nih.gov/ij/, 1997-2012). Quantification was performed on 3-5 randomly 
selected ventricular sections from 4 animals each group and was expressed as fold changes with 
respect to the control normalized value. 
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To study the occurrence of cardiomyocyte hypertrophy, photomicrographs of Masson’s trichrome 
stained ventricular sections were taken (400× magnification). Thus, the cross-sectional area of 
cardiomyocytes was measured with IM50 software (Leica Microsystem) by tracing the outlines of 
those positioned perpendicular to the plane of the section and with a clear nucleus image, in accord 
with Kelly’s method 30. Typically, about 200 cardiomyocyte cross-sectional areas were measured 
and averaged for each group. 
 
Metalloproteinase activity 
Latent (72 kD) and active (66 kD) forms of MMP-2 as well as latent (92 kD) and active (82 kD) 
forms of MMP-9 were detected by gelatin zymography 31. Briefly, samples of frozen heart were 
powdered and resuspended in RIPA buffer for protein extraction. One hundred micrograms of total 
proteins were separated by SDS–PAGE on a 10% acrylamide gel, containing 0.1% gelatin under 
non-reducing conditions. Gels were washed in renaturing buffer (2.5% Triton X-100 in distilled 
water) for 30 min at room temperature with gentle agitation, and then in distilled water. Afterword, 
they were equilibrated and incubated in developing buffer (50 mM Tris-HCl, pH 7.8, 0.2M NaCl, 
5mM CaCl2, and 0.02% v/v Tween-20) overnight at 37°C. Gels were stained with 0.05% w/v 
Coomassie Brilliant Blue, 5% v/v methanol and 10% v/v acetic acid in distilled water for 1 h at 
room temperature and then destained with a 10% v/v methanol and 5% v/v acetic acid solution. 
Bands quantification was performed with ImageJ software. 
 
Protein level expression 
Western blot analysis was performed as previously described 32. After protein extraction and 
quantification (Bradford protein assay), 100 µg of total proteins were separated on 10% SDS–
PAGE, and electrotransferred to a PVDF membrane (Macherey-Nagel, Düren, Germany). 
Membranes were incubates with specific primary antibodies against TGF-β1, TIMP-1 and β-myosin 
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heavy chain (β-MHC) and thus with species-specific horseradish peroxidase-conjugate secondary 
antibodies (Table 1). The expression of β-actin was evaluated in the same blot as loading control. 
Immunolabeled bands were detected using enhanced chemiluminescence (ECL) system (BioVision, 
Mountain View, CA, USA). Image acquisition and quantification were made with a Kodak Image 
station 440CF (Kodak, Rochester, NY, USA). Each experiment was done in triplicate. 
 
Statistical analysis 
The experimental data are expressed as the mean of technical and biological replicates ± SD. 
Statistical significance was assessed by one-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test, and significant differences were accepted with p<0.05 as the significant cut-off. 
All analyses were carried out with GraphPad Prism version 6.0c (GraphPad Software, San Diego 
California, USA). 
 
Results 
In vitro Studies 
ALA prevents ISO-induced H9c2 cell viability impairment 
MTT assays (fig. 2) demonstrated that the viability of H9c2 cells was significantly reduced to 
59.9±8.6% (p<0.001) after 24h of incubation with ISO at 250 µM concentration. When ISO 
treatment was preceded by 24 h incubation with ALA, H9c2 cell viability was reduced only to 
89.2±12.8% with respect to controls (p<0.05), strongly counteracting the impairments provoked by 
ISO (p<0.001). 
The pretreatment with the PI3K inhibitor LY294002, the Src inhibitor PP2 or with the caveolae 
disrupter MβCD suppressed the ALA-mediated protection from ISO damage on H9c2 cell viability 
(59.4±14.9%, 63.6±11.4% and 64.4±15.5%, respectively). None of these groups was significantly 
different from ISO group, but they were significantly reduced in cell viability if compared to ALA-
ISO group (each p<0.001). 
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In vivo Studies 
ALA-enriched diet abolishes animal mortality during ISO treatment 
Repeated subcutaneous injection of ISO provoked an high acute mortality rate (50%) amongst rats 
of ISO group, which were fed with standard diet. Fatal occurrences took place in the period of ISO 
treatment (2 animals after the first day, 3 animals after the second day, and 2 more after the fourth 
day) while no other rats died until the end of the experimentation. No deaths were observed after 
ISO injection in rats fed with the ALA-enriched diet, as well as in those of CTRL group, which 
were injected with saline solution. 
 
ALA-enriched diet prevents the reduction of heart mechanical function 
After the treatment with either ISO or saline, rats were followed for 60 days in which EF and FS 
were monitored. In CTRL group both parameters did not change during the observation period. On 
the other hand, EF and FS decreased significantly in ISO group by about 10% and 15% respectively 
(p<0.01). The decrease was almost the same 30 and 60 day after the end of treatment. The ISO-
induced reduction of cardiac function did not occur when the animals were fed with ALA-enriched 
diet (Fig. 3a and 3b). 
 
ALA-enriched diet prevents ISO-induced cardiac fibrosis 
The extension of cardiac fibrosis was assessed with Masson’s trichrome staining. Hearts from 
control group showed weak expression of extracellular matrix (Fig. 4a). On the contrary, a 
remarkable production and deposition of ECM occurred in the hearts of ISO group, where newly 
formed collagen mainly surrounded cardiomyocytes throughout entire ventricular sections (Fig. 4b). 
In hearts from ALA-ISO group, the expression and localization of the ECM were similar to those 
observed in control hearts (Fig. 4c). In the Masson’s trichrome staining, the fibrotic area increased 
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about 8 fold in ISO group with respect to CTRL, while it did not show any appreciable change in 
ALA-ISO group (Fig. 4d). 
These data were supported by the increased activity of both latent and active forms of MMP-2 
(p<0.05 and p<0.01, respectively) by about 50% in the ISO group with respect to CTRL (Fig. 5a). 
Such increases were prevented when the ISO-treated animals were fed with ALA-enriched diet. 
Unlike MMP-2, the activity of MMP-9 was not detectable in our experiments. In addition, the 
expression of the inhibitor of metalloproteinase TIMP-1 was reduced by about 25% in response to 
ISO treatment, while no changes were observed when the treated animals were fed with the ALA-
enriched diet (Fig. 5b). Also a four-fold increase in expression (p<0.001) of TGF-β1 took place in 
the ISO group, while no change occurred in ALA-ISO group (Fig. 5c). 
 
ALA-enriched diet prevents ISO-induced cardiac hypertrophy 
During the observation period, the weight of the animals increased with time from 144±8 to 334±20 
g in CTRL, from 145±5 to 334±17 g in ISO group and from 144±4 to 320±9 g in ALA-ISO group, 
without any significant difference among the groups. 
At the post-mortem examination, the heart weights were significantly (p<0.01) higher in ISO group 
(1.36±0.06 g) with respect to CTRL (1.08±0.16 g) and ALA-ISO group (1.07±0.15 g). No 
significant difference was found between CTRL and ALA-ISO groups.  
The heart/body weight ratio was 3.31±0.40‰ in CTRL. It was slightly but significantly increased in 
ISO group (4.04±0.16‰; p<0.01), while it remained unchanged when animals were fed with ALA-
enriched diet (3.23±0.44‰) (Fig. 6a). The above data on cardiac hypertrophy were supported by the 
histological examination, which consider 200 cardiomyocytes for each experimental group. An 
increase in cardiomyocyte cross-sectional area was detected in ISO group (250±10  µm2; p<0.001) 
with respect to the CTRL (199±3  µm2), while no significant differences were found between CTRL 
and ALA-ISO (198±2  µm2) groups (Fig. 6b). In addition to TGF-β1 overexpression (Fig. 5c) that is 
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also associated with myocardial hypertrophy, a 3-fold increased expression (p<0.001) in β-MHC, a 
marker of pathological cardiac hypertrophy, was observed in ISO group. This increase did not occur 
if the animals were fed with an ALA-enriched diet (Fig. 6c). 
 
Discussion 
The present investigation demonstrated that ALA prevents cardiac damage induced by β-adrenergic 
overstimulation.  
In cardiovascular diseases, β-adrenergic receptors (βAR) trigger a broad range of pathways, which 
lead to the progressive degeneration of myocardium. The mining analysis of βAR-triggered 
pathways reveals the involvement of more than one hundred molecules (Fig S1), which are 
accountable for about five hundred interactions. These pathways could be however responsible for 
either tissue remodeling (fibrosis and hypertrophy) or cell survival, on the basis of the different 
location of βAR subtypes. 
In fact, β1ARs are present on the cell membrane where they are exclusively coupled with Gs protein, 
which triggers the increase of cAMP levels 33 and induces myocyte apoptosis and necrosis 34, 
cardiac fibrosis 10 and hypertrophy 11. Unlike these receptors, β2ARs can be confined into the 
caveolae, where they are coupled with Gi protein, thus impairing cAMP production and activating a 
pro-survival pathway 33, 35-37. Chronic βAR over-stimulation also induces the downregulation of 
caveolin-3 38, the structural component of caveolae, allowing β2AR to move out of caveolae where 
they mediate the same effects of β1AR 33, 35, 39.  
In order to validate the hypothesis that ALA can exert protective effect against βAR over-
stimulation, we performed an in vitro study, which showed that ALA treatment limited the 
isoproterenol-induced H9c2 impairment of viability. This effect was due to the activation of a 
pathway involving Src kinase and PI3K, as demonstrated by its suppression after the cells were pre-
incubated with PP2 and LY294002. These specific inhibitors abolished the pathway elicited by Gi 
protein coupled β2AR stimulation 37 and the resulting myocardial protection, but were ineffective 
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when βARs interacted with Gs protein 40. A similar pro-survival suppression occurred after caveolae 
disruption with MβCD and demonstrated that the integrity of caveolae is essential to allow ALA to 
exert the protective effect. These results are consistent with the reported capability of ALA to 
enhance caveolin-3 level and preserve the integrity of caveolae 20. 
ISO administration was reported to reduce caveolin-3 expression and caveolae density 33, 38, 41-43. 
The dislocation of β2AR out of caveolae and its coupling with Gs protein may contribute to β1AR-
induced TGF-β overexpression leading to fibrosis and hypertrophy. It is likely that if ALA 
preserves the integrity of caveolae 20, the pro-survival pathway can be triggered 37, 44, since the 
caveolar membrane is characterised by a hight content of Gi protein-coupled β2AR 36, 45. Hence, 
ALA protective effect was studied in rats using a well-known experimental model of infarct-like 
myocardial damage obtained by repeated injections of ISO 22, 23. The enrichment of ALA was 
achieved employing an already validated diet, which was used to address the role of ALA mediated 
protection in cardiomyocytes and hamsters with genetic cardiomyopaties 18, 20, 21. Here, we estimate 
that 2.85 g/day of ALA was assumed by each rat. Interestingly, treatment with similar amount of 
ALA (2.9 g/day) was also reported in human where it significantly lower the risk to undergo both 
cardiac death and nonfatal myocardial infarction 46. 
In the present investigation we demonstrate that an ALA-enriched diet preserves the heart from the 
injuries caused by adrenergic overstimulation. During ISO treatment, 50% of the animals died, 
presumably as a result of arrhythmias caused by spatial dispersion of action potential duration as 
previously demonstrated 47. ALA-enriched diet may have suppressed this mortality because of an 
anti-arrhythmic effect mediated by the reduction of myocardial excitability 48 and the shortening of 
action potential duration 49. 
As expected, 60 days after the end of the treatment, the histological examination of hearts from ISO 
group revealed the presence of fibrosis and hypertrophy, i.e. an abundant deposition of ECM among 
cardiomyocytes and an increase in cell size. These morphological alterations were accompanied by 
an increased expression of TGF-β and β-MHC, a decrease of TIMP-1 expression and an increase in 
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the activity of both latent and active forms of MMP-2, as it was found in the late remodeling phase 
of myocardial infarction 50, 51.  
The increased expression of TGF-β by β-adrenergic overstimulation 52 is responsible for both 
fibrosis and hypertrophy. In the case of fibrosis, TGF-β causes the differentiation of fibroblasts into 
myofibroblasts, thus leading to an excess of ECM production via a complex regulation of MMP and 
TIMP interaction 53. Actually, the regulatory role of TGF-β on MMP/TIMP system is rather 
complex because MMP-2 can in turn promote the activity of TGF-β through the proteolytical 
cleavage of its latent form 54. Because of this positive feedback, the role of TGF-β and MMP/TIMP 
system in inducing myocardial fibrosis is strengthened. Although the active form of MMP-2 is 
generally accompanies by MMP-9 activity during the fibrosis onset 55, in our experiments MMP-9 
activity was not present. The absence was in line with the short persistence of this enzyme after the 
induction of a myocardial damage 50, 56 and was also supported by the mining analysis. 
In the case of hypertrophy, TGF-β mediates the upregulation of β-MHC RNA expression, the 
increase of cardiomyocyte protein content, the sarcomeric organization and cell size 57. It has been 
suggested that in hypertensive rats an increased MMP activity may be involved in hypertrophy, and 
that this enhanced activity is accompanied by an increase in TGF-β expression 58, so that it is 
difficult to deal with these two processes separately. 
In the myocardium of animals fed with ALA-enriched diet, ISO was not able to provoke any of the 
above mentioned histological and molecular alterations, leaving the various markers in the range of 
the healthy controls. The present findings provide evidence for the first time that ALA counteracts 
TGF-β overexpression and the increase in MMP activity in the rat heart, thus preventing the ISO-
induced fibrosis and hypertrophy. The abolishment of the protection after disruption of the caveolae 
suggests the possibility that a shift in the β2AR signaling from Gi to Gs by ISO administration is 
prevented when ALA preserves the integrity of caveolae. 
ISO-treated animals displayed a decrement in contractility, as revealed by reduced EF and FS. Since 
it has been demonstrated that MMP-2 can per se impair ventricular function in the absence of 
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superimposed injury, it is possible that MMP-2 contributed to the reduction of EF and FS even 
independently of the fibrosis 59, 60. It may then be argued that flaxseed supplementation maintained 
a physiological contractility because ALA prevented both structure derangement and functional 
impairment of myocardium. 
In conclusion, the present study demonstrated that ALA effectiveness is due to the preservation of 
caveolae integrity that are essential for the activation of the Src-PI3K pro-survival pathway. 
Moreover, ALA-enriched diet reduces mortality and prevents cardiac fibrosis, hypertrophy as well 
as mechanical dysfunction induced by the β-adrenergic overstimulation in these experimental 
models.  
Our data provide the basis for the development of future appropriate strategies for the prevention of 
various pathophysiological conditions characterized by a sympathetic overactivity. In particular, 
further studies are required to fully unravel the mechanism underlying β-adrenergic over-
stimulation and to clarify whether ALA is protective also in other types of cardiac remodeling. 
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Figure legends 
 
Figure 1 In vivo experimental protocols. Each bar summarizes the treatments and the diets 
followed by the animals of the three experimental groups. Control (CTRL), isoproterenol (ISO) and 
α- linolenic acid (ALA). 
 
Figure 2 α-linolenic acid (ALA) prevented ISO-induced impairment of H9c2 cell viability. The 
addition of specific inhibitors (LY294002 or PP2) and of caveolae disrupter (MβCD) completely 
reverted the ALA mediated protection. Values are means ± SD. * p<0.05 and *** p<0.001 vs. 
control (CTRL); ### p<0.001 vs. ALA-ISO. 
 
Figure 3 α-linolenic acid (ALA)-enriched diet counteracted isoproterenol (ISO)-induced alterations 
of heart mechanical function. Reduction of left ventricular ejection fraction (EF) (a) and fractional 
shortening (FS) (b) in ISO group 30 and 60 days after the end of ISO-treatment. No change was 
observed in control (CTRL) and ALA-ISO groups. Values are means ± SD. * p<0.05 and ** 
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p<0.01 vs CTRL; ## p<0.01 and ### p<0.001 vs ALA-ISO group; § p<0.05 and §§ p<0.05 vs basal 
condition (0 day). 
 
Figure 4 α-linolenic acid (ALA)-enriched diet prevented isoproterenol (ISO)-induced fibrosis in 
ventricular myocardium. Masson’s trichrome stained ventricular section showed a basal deposition 
of extracellular matrix in control (CTRL) (a) which heavily increased after ISO treatment (b). The 
increase was prevented by ALA-enriched diet (c). The images are representative of randomly 
selected slices (scale bar=500 µm). Quantification of collagen deposition (d) was expressed as fold 
changes with respect to the normalized control value. ***p<0.001 vs CTRL; ###p<0.001 vs ALA-ISO 
group. 
 
Figure 5 α-linolenic acid (ALA)-enriched diet effect on isoproterenol (ISO)-induced alterations of 
molecular markers of fibrosis. ALA-enriched diet prevented the increase in active and latent MMP-
2 after ISO treatment (a); ALA-enriched diet prevented the reduction in TIMP-1 and the increase in 
TGF-β protein expressions. Band intensities were normalized to β-actin expression Values are 
means ± SD. * p<0.05 and ** p<0.01 vs. control (CTRL); # p<0.05, ## p<0.01 and ### p<0.001 vs. 
ALA-ISO group. 
 
Figure 6 α-linolenic acid (ALA)-enriched diet protected ventricular myocardium against 
isoproterenol (ISO)-induced hypertrophy by preventing increase of HW/BW ratio (a); increase of 
cardiomyocyte cross-sectional (CSA) with representative images of randomly selected slices (scale 
bar=50 µm) (b); increase of β- myosin heavy chain (β-MHC) expressions (c);. Values are means ± 
SD. ** p<0.01 and *** p<0.001 vs. control (CTRL); ## p<0.01 and ### p<0.001 vs. ALA-ISO. 
 
Table 1. Antibodies employed for Western Blot analysis 
Primary Ab Clone Host Dilution Supplier 
TGF-β1 V Rabbit 1:200 SantaCruz Biotechnology, Inc 
TIMP-1 H150 Rabbit 1:200 SantaCruz Biotechnology, Inc 
β-MHC NOQ7.5.4D Mouse 1:1000 Sigma-Aldrich 
β-actin C11 Rabbit 1:1000 Sigma-Aldrich 
Secondary Ab Reactivity Host Dilution Supplier 
IgG-HRP Rabbit Goat 1:2000 SantaCruz Biotechnology, Inc 
IgG-HRP Mouse Goat 1:2000 SantaCruz Biotechnology, Inc 
Abbreviations: TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; MHC, myosin 
heavy chain; HRP, horseradish peroxidase. 







Supplementary data 	  
Materials and Methods 
Data mining 
ProteinQuest™ literature mining tool (BioDigitalValley S.r.l., Pont-Saint-Martin, Aosta, Italy) was 
used to detect correlations and interactions in the β-adrenergic receptor downstream signaling 
pathways. In particular, the query ["Adrenoceptor beta proteins" AND Myocardium AND ("Heart 
Failure" Or "Myocardial Ischemia")] was investigated. The analysis of literature obtained by the 
ProteinQuest™ mining tool detected 344 papers, from which 114 network nodes (proteins) and 499 
edges (interactions) were retrieved. Reactome FI app 1 for Cytoscape 2 version 3.2.0 
(http://www.cytoscape.org) was employed to analyse pathways and networks (Fig. S1). Among 
these, Caveolin-3 (CAV3) and PI3K, as well as Src kinase (retrievable as linked to PI3K in further 
analysis refinements), were assessed for their involvement in cell survival. The role of TIMP1 and 
MMP2 were investigated to address the fibrosis onset. β-myosin heavy chain (MYH7, β-MHC) was 
employed as marker of hypertrophy, while TGF-β1 was recruited as marker of both fibrosis and 
hypertrophy. 	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Supplementary figure legends 
Figure S1 Data mining. Reactome FI representation of the analysis performed by Protein Quest™. 
β1AR and β2AR where circled in red while the main actors and object of our investigation were 
highlighted in yellow. Coloured areas represent cell survival (green), fibrosis (blue), hypertrophy 
(red), or their ovelapping. 	  	  
